PPT Slide

CON’S

• Weak anti – H. influenzae activity

• Only orally

• Commercial benefits =  flu-like syndroms, URTI, AECB: resistance

• Studies in peni- and erythro-R CAPs needed

• Further data on cardiotoxicity (QTc) needed

TELITHROMYCIN in CAP

Previous slide

Next slide

Back to first slide

View graphic version